News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UCB Group to Launch Epilepsy Drug in Autumn
June 27, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRUSSELS, June 27 (Reuters) - Shares in UCB SA jumped on Friday as the Belgian pharmaceutical group said it aimed to launch its new epilepsy drug Vimpat in the autumn, after winning a green light from the European Medicines Agency.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
HIV
Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries
September 5, 2025
·
1 min read
·
Tristan Manalac
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
·
4 min read
·
Annalee Armstrong
CDC
ACIP Revamp Continues as Kennedy Eyes Seven New CDC Vaccine Advisors
September 4, 2025
·
2 min read
·
Dan Samorodnitsky
Regulatory
‘All Wrapper, No Gift’: FDA Releases New Rare Disease Approval Framework
September 4, 2025
·
2 min read
·
Tristan Manalac